

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA

HBM BioVentures

Press release

Zug, 31 August 2011

HBM BioVentures Investor Information

At its investor event today, HBM BioVentures will report on the company's current status after several profitable major trade sales from the portfolio that have been made this year. The presentation shown at the event can be viewed at www.hmbioventures.com.

As at 24 August, HBM BioVentures held 20% of its net assets as cash and cash equivalents*, 52% in private investments, 19% in public investments and 9% in other assets. HBM BioVentures is 99% equity-financed*. The company's liquidity thus is more than sufficient. The majority of HBM BioVentures' USD currency risk is hedged at the current CHF/USD exchange rate level of 0.81. The opportunity to benefit from a USD appreciation remains in place.

(* = pro forma, following the redemption of the CHF 30 million bond in December 2011)

For further information, please contact Dr. Andreas Wicki, CEO of HBM BioVentures Ltd, tel.: +41 41 768 11 08, andreas.wicki@hmbioventures.com.

HBM BioVentures Ltd

HBM BioVentures is invested globally in some 25 mature companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The lead products of many companies in HBM BioVentures' portfolio are either at an advanced stage of development or already available on the market. The investment focus currently is on follow-on financing for still-private companies in the portfolio that offer high value-creation potential. HBM BioVentures is an interesting alternative to investments in big pharma and biotech companies. HBM BioVentures has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities

HBM BioVentures Ltd
Bundesplatz 1
CH-6300 Zug / Switzerland
Tel:+41 41 768 11 08
Fax:+41 41 768 11 09
info@hmbioventures.com
www.hmbioventures.com

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA



Prospectus Act (Wertpapierprospektgesetz). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM BioVentures Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

HBM BioVentures Ltd
Bundesplatz 1
CH-6300 Zug / Switzerland
Tel:+41 41 768 11 08
Fax:+41 41 768 11 09
info@hbmbioventures.com
www.hbmbioventures.com